Orion Oyj (0M2N.L)

33,55 +0,05 (+0,15%) Börsenschluss: 05:10PM BST

Orion Oyj

Orionintie 1A
Espoo 02200
Finland
358 10 4261
https://www.orion.fi

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 3.698

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Liisa Hurme	President, CEO & Chairman of Executive Management Board	770,28k	N/A	1967
Mr. Rene Lindell M.Sc., Ph.D.	Chief Financial Officer & Member of Group Executive Management Board	N/A	N/A	1976
Mr. Olli Huotari Ll.M.	Senior VP of Corporate Functions, General Counsel, Secretary & Member of Executive Management Board	N/A	N/A	1966
Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.)	Senior VP of Generics and Consumer Health Business Division & Member of the Exe. Mgmt. Board	N/A	N/A	1966
Prof. Outi Vaarala M.D., Ph.D.	Sr. VP of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. Board	N/A	N/A	1962
Mr. Juhani Kankaanpaa	Senior VP of Global Operations & Member of Executive Management Board	N/A	N/A	N/A
Mr. Niclas Lindstedt EMBA, M.Sc.	Senior VP of Animal Health Business Division & Member of the Exe. Mgmt. Board	N/A	N/A	N/A
Mr. Hao Pan M.Sc.	Senior VP of the Branded Products Business Division & Member of the Exe. Mgmt. Board	N/A	N/A	1971
Ms. Julia Irene Macharey	Senior Vice President of People & Culture and Member of Management Board	N/A	N/A	1977
Mr. Tuukka Hirvonen M.Sc.(Soc.)	Investor Relations & Financial Communications Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Corporate Governance

Orion Oyjs ISS Governance QualityScore, Stand 1. Mai 2024, lautet 3. Die grundlegenden Scores sind Audit: 4, Vorstand: 1, Shareholderrechte: 10, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.